Cargando…
Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2
BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key player in lipid metabolism, as it degrades low-density lipoprotein (LDL) receptors from hepatic cell membranes. So far, only variants of the PCSK9 gene locus were found to be associated with PCSK9 levels. Here we aimed to ide...
Autores principales: | Pott, Janne, Gådin, Jesper R, Theusch, Elizabeth, Kleber, Marcus E, Delgado, Graciela E, Kirsten, Holger, Hauck, Stefanie M, Burkhardt, Ralph, Scharnagl, Hubert, Krauss, Ronald M, Loeffler, Markus, März, Winfried, Thiery, Joachim, Silveira, Angela, van't Hooft, Ferdinand M, Scholz, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947322/ https://www.ncbi.nlm.nih.gov/pubmed/34590679 http://dx.doi.org/10.1093/hmg/ddab279 |
Ejemplares similares
-
Disruption of the ERLIN–TM6SF2–APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease
por: Li, Bo-Tao, et al.
Publicado: (2020) -
Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study
por: Eshraghian, Ahad, et al.
Publicado: (2021) -
The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021) -
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019) -
Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)